Your browser doesn't support javascript.
loading
Noncanonical TGFß Pathway Relieves the Blockade of IL1ß/TGFß-Mediated Crosstalk between Tumor and Stroma: TGFBR1 and TAK1 Inhibition in Colorectal Cancer.
Guillén Díaz-Maroto, Natalia; Sanz-Pamplona, Rebeca; Berdiel-Acer, Mireia; Cimas, Francisco J; García, Elena; Gonçalves-Ribeiro, Samuel; Albert, Nerea; Garcia-Vicién, Gemma; Capella, Gabriel; Moreno, Victor; Salazar, Ramon; Villanueva, Alberto; Molleví, David G.
Afiliação
  • Guillén Díaz-Maroto N; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Sanz-Pamplona R; Biomarker and Susceptibility Unit, Program for Cancer Control and Prevention, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Berdiel-Acer M; German Cancer Research Center, Division of Molecular Genome Analysis, Heidelberg, Germany.
  • Cimas FJ; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • García E; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Gonçalves-Ribeiro S; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Albert N; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Garcia-Vicién G; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Capella G; Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Moreno V; Biomarker and Susceptibility Unit, Program for Cancer Control and Prevention, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Salazar R; ONCOBELL Program, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Villanueva A; ProCURE, Program Against Cancer Therapeutic Resistance, Catalan Institute of Oncology, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
  • Molleví DG; ONCOBELL Program, IDIBELL, L'Hospitalet de Llobregat, Catalonia, Spain.
Clin Cancer Res ; 25(14): 4466-4479, 2019 07 15.
Article em En | MEDLINE | ID: mdl-30979739
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Células Estromais / MAP Quinase Quinase Quinases / Interleucina-1beta / Fator de Crescimento Transformador beta1 / Fibroblastos Associados a Câncer / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Células Estromais / MAP Quinase Quinase Quinases / Interleucina-1beta / Fator de Crescimento Transformador beta1 / Fibroblastos Associados a Câncer / Receptor do Fator de Crescimento Transformador beta Tipo I Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article